立体定向体部放疗治疗肺癌肾上腺转移的短期结局与临床疗效
这项回顾性两机构研究纳入2006年10月至2016年6月接受SBRT的30例肺癌肾上腺转移患者(32个病灶),中位随访10.7个月;6个月、1年、2年局部控制率分别为96.9%、96.9%、72.7%,仅1例出现3级腹泻,所有癌性疼痛患者症状均获显著缓解。
要点
- 30例患者32个病灶接受SBRT,6个月、1年、2年局部控制率分别为96.9%、96.9%、72.7%。
- 6个月、1年、2年总生存率分别为85.6%、58.1%、54.0%。
- 仅1例出现3级腹泻,所有癌性疼痛患者疼痛均显著缓解。
核心结论
- SBRT是治疗肺癌肾上腺转移安全有效的方式,局部控制率高且毒性可接受。
研究设计与样本
- 回顾性两机构研究,纳入2006年10月至2016年6月接受SBRT的30例肺癌肾上腺转移患者(27男、3女),共32个病灶;11例以控制全部已知转移灶为目的,19例为姑息治疗 bulky 肾上腺转移灶;每3个月随访评估疗效与安全性。
主要发现
- 中位随访10.7个月(范围2.9-96.4个月);完全缓解率23.3%、部分缓解率33.3%、疾病稳定率33.3%、疾病进展率16.7%。
- 6个月、1年、2年局部控制率分别为96.9%、96.9%、72.7%。
- 6个月、1年、2年总生存率分别为85.6%、58.1%、54.0%;6个月、1年、2年无进展生存率分别为39.5%、24.6%、8.2%。
- 所有癌性疼痛患者(8例腹痛、6例腰背痛)在SBRT后均获显著缓解;仅1例报告3级腹泻。
- 单因素分析显示BED10(α/β=10)≥85.5Gy(P=0.007)和GTV<30ml(P=0.003)与局部控制相关,多因素分析未发现总生存和局部控制的预测因素。
关键数值与推荐
- 完全缓解率23.3%、部分缓解率33.3%、疾病稳定率33.3%、疾病进展率16.7%。
- 6个月、1年、2年局部控制率分别为96.9%、96.9%、72.7%。
- 6个月、1年、2年总生存率分别为85.6%、58.1%、54.0%,无进展生存率分别为39.5%、24.6%、8.2%。
- 单因素分析中BED10≥85.5Gy(P=0.007)和GTV<30ml(P=0.003)与局部控制相关。
临床怎么用
- 原文结论认为SBRT是治疗肺癌肾上腺转移安全有效的方式,局部控制率高且毒性可接受。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the efficacy and safety of stereotactic body radiation therapy (SBRT) in the management of adrenal gland metastases (AGMs) from lung cancer. Moreover, it is the first two-institutional experience and the largest-to-date study to report the safety and efficacy of SBRT for inoperable AGM from lung cancer. METHODS: In this retrospective study, 30 patients (27 males, 3 females) with 32 AGMs were treated by SBRT from October 2006 to June 2016. Of these, 11 patients were treated with the intent of controlling all known metastatic sites and 19 for palliation of bulky AGMs. Follow-up was performed every 3 months for evaluations of efficacy and safety. Factors predictive of overall survival (OS) and local control (LC) were identified with univariate and then multivariate analysis. RESULTS: Median follow-up time was 10.7 months (2.9-96.4 months). The complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) rates were 23.3%, 33.3%, 33.3% and 16.7% respectively. The 6-month, 1, and 2-year LC rates were 96.9%, 96.9%, and 72.7% respectively. Additionally, the 6-month, 1, and 2-year OS rates were 85.6%, 58.1%, and 54.0% respectively while 6-month, 1, and 2-year progression free survival (PFS) rates were 39.5%, 24.6%, and 8.2%, respectively. All the patients with cancer-induced pain (8 with abdominal pain and 6 with lumbar back pain) had significant alleviations after SBRT. The treatment was well tolerated with only 1 patient reporting grade-3 diarrhoea. No predictors of OS and LC were found after multivariate analysis, while it was demonstrated that biologic equivalent dose (BED10, α/β = 10) ≥85.5Gy (P = 0.007) and gross tumor volume < 30 ml (P = 0.003) correlated with LC only after univariate analysis. CONCLUSION: SBRT is a safe and effective treatment modality in the management of AGMs from lung cancer with high LC rates and acceptable toxicity.
引用
- Zhao X, Zhu X, Fei J, et al. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer. Radiat Oncol. 2018. PMID: 30348187. doi:10.1186/s13014-018-1152-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。